dusigitumab (MEDI-573) / AstraZeneca  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dusigitumab (MEDI-573) / AstraZeneca
IGF-1: MEDI-573 is in Phase 2 for Breast Cancer

Ongoing
2
0
RoW
MEDI-573
Astrazeneca
Breast cancer
 
 
NCT01498952: MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

Completed
1b/2
6
US
MEDI-573 (1 of 3 doses), Sorafenib
MedImmune LLC
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
04/13
04/13
NCT01446159 / 2011-000198-29: Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Checkmark Of P1/2 trial for metastatic breast cancer
Sep 2019 - Sep 2019: Of P1/2 trial for metastatic breast cancer
Completed
1b/2
188
Europe, Canada, US, RoW
MEDI-573, Aromatase Inhibitor
MedImmune LLC
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
06/19
06/19

Download Options